Clinical characteristics of advanced non-small cell lung cancer patients with EGFR exon 20 insertions
Abstract Epidermal growth factor receptor (EGFR) exon 20 insertion mutations (Exon20ins) account for 4–12% of all EGFR mutations in non-small cell lung cancer (NSCLC) patients. Data on the differences in clinical characteristics between patients with Exon20ins and major mutations (M-mut) such as exo...
Guardado en:
| Autores principales: | , , , , , , , , , , , , , |
|---|---|
| Formato: | article |
| Lenguaje: | EN |
| Publicado: |
Nature Portfolio
2021
|
| Materias: | |
| Acceso en línea: | https://doaj.org/article/3e86b2e7f167471e865402ee946d66a0 |
| Etiquetas: |
Agregar Etiqueta
Sin Etiquetas, Sea el primero en etiquetar este registro!
|
| id |
oai:doaj.org-article:3e86b2e7f167471e865402ee946d66a0 |
|---|---|
| record_format |
dspace |
| spelling |
oai:doaj.org-article:3e86b2e7f167471e865402ee946d66a02021-12-02T18:13:52ZClinical characteristics of advanced non-small cell lung cancer patients with EGFR exon 20 insertions10.1038/s41598-021-98275-32045-2322https://doaj.org/article/3e86b2e7f167471e865402ee946d66a02021-09-01T00:00:00Zhttps://doi.org/10.1038/s41598-021-98275-3https://doaj.org/toc/2045-2322Abstract Epidermal growth factor receptor (EGFR) exon 20 insertion mutations (Exon20ins) account for 4–12% of all EGFR mutations in non-small cell lung cancer (NSCLC) patients. Data on the differences in clinical characteristics between patients with Exon20ins and major mutations (M-mut) such as exon 19 deletion and L858R are limited. We retrospectively reviewed advanced NSCLC patients with EGFR mutations, who were treated with systemic therapy between January 2011 and December 2019. We identified 23 patients with Exon20ins and 534 patients with M-mut. In Exon20ins patients, the median age was 60 (range 27–88) years, and females and never-smokers were predominant. Clinical characteristics were similar in the two groups. In Exon20ins patients, 17 patients received platinum doublet as first-line therapy, and the overall response rate (ORR) and median progression-free survival (mPFS) were 11.8% and 8.9 months. Additionally, seven patients received conventional EGFR-tyrosine kinase inhibitors (TKIs), and eight patients anti-PD-1 antibodies in any-line therapy. ORR and mPFS of EGFR-TKIs and anti-PD-1 antibodies were 0%, 2.2 months and 25%, 3.1 months, respectively. Overall survival was significantly shorter in Exon20ins patients than in M-mut patients (29.3 vs. 43.4 months, p = 0.04). The clinical outcomes in Exon20ins patients were not satisfactory compared to M-mut patients.Chie MoritaTatsuya YoshidaMasayuki ShirasawaKen MasudaYuji MatsumotoYuki ShinnoShigehiro YagishitaYusuke OkumaYasushi GotoHidehito HorinouchiNoboru YamamotoNoriko MotoiYasushi YatabeYuichiro OheNature PortfolioarticleMedicineRScienceQENScientific Reports, Vol 11, Iss 1, Pp 1-7 (2021) |
| institution |
DOAJ |
| collection |
DOAJ |
| language |
EN |
| topic |
Medicine R Science Q |
| spellingShingle |
Medicine R Science Q Chie Morita Tatsuya Yoshida Masayuki Shirasawa Ken Masuda Yuji Matsumoto Yuki Shinno Shigehiro Yagishita Yusuke Okuma Yasushi Goto Hidehito Horinouchi Noboru Yamamoto Noriko Motoi Yasushi Yatabe Yuichiro Ohe Clinical characteristics of advanced non-small cell lung cancer patients with EGFR exon 20 insertions |
| description |
Abstract Epidermal growth factor receptor (EGFR) exon 20 insertion mutations (Exon20ins) account for 4–12% of all EGFR mutations in non-small cell lung cancer (NSCLC) patients. Data on the differences in clinical characteristics between patients with Exon20ins and major mutations (M-mut) such as exon 19 deletion and L858R are limited. We retrospectively reviewed advanced NSCLC patients with EGFR mutations, who were treated with systemic therapy between January 2011 and December 2019. We identified 23 patients with Exon20ins and 534 patients with M-mut. In Exon20ins patients, the median age was 60 (range 27–88) years, and females and never-smokers were predominant. Clinical characteristics were similar in the two groups. In Exon20ins patients, 17 patients received platinum doublet as first-line therapy, and the overall response rate (ORR) and median progression-free survival (mPFS) were 11.8% and 8.9 months. Additionally, seven patients received conventional EGFR-tyrosine kinase inhibitors (TKIs), and eight patients anti-PD-1 antibodies in any-line therapy. ORR and mPFS of EGFR-TKIs and anti-PD-1 antibodies were 0%, 2.2 months and 25%, 3.1 months, respectively. Overall survival was significantly shorter in Exon20ins patients than in M-mut patients (29.3 vs. 43.4 months, p = 0.04). The clinical outcomes in Exon20ins patients were not satisfactory compared to M-mut patients. |
| format |
article |
| author |
Chie Morita Tatsuya Yoshida Masayuki Shirasawa Ken Masuda Yuji Matsumoto Yuki Shinno Shigehiro Yagishita Yusuke Okuma Yasushi Goto Hidehito Horinouchi Noboru Yamamoto Noriko Motoi Yasushi Yatabe Yuichiro Ohe |
| author_facet |
Chie Morita Tatsuya Yoshida Masayuki Shirasawa Ken Masuda Yuji Matsumoto Yuki Shinno Shigehiro Yagishita Yusuke Okuma Yasushi Goto Hidehito Horinouchi Noboru Yamamoto Noriko Motoi Yasushi Yatabe Yuichiro Ohe |
| author_sort |
Chie Morita |
| title |
Clinical characteristics of advanced non-small cell lung cancer patients with EGFR exon 20 insertions |
| title_short |
Clinical characteristics of advanced non-small cell lung cancer patients with EGFR exon 20 insertions |
| title_full |
Clinical characteristics of advanced non-small cell lung cancer patients with EGFR exon 20 insertions |
| title_fullStr |
Clinical characteristics of advanced non-small cell lung cancer patients with EGFR exon 20 insertions |
| title_full_unstemmed |
Clinical characteristics of advanced non-small cell lung cancer patients with EGFR exon 20 insertions |
| title_sort |
clinical characteristics of advanced non-small cell lung cancer patients with egfr exon 20 insertions |
| publisher |
Nature Portfolio |
| publishDate |
2021 |
| url |
https://doaj.org/article/3e86b2e7f167471e865402ee946d66a0 |
| work_keys_str_mv |
AT chiemorita clinicalcharacteristicsofadvancednonsmallcelllungcancerpatientswithegfrexon20insertions AT tatsuyayoshida clinicalcharacteristicsofadvancednonsmallcelllungcancerpatientswithegfrexon20insertions AT masayukishirasawa clinicalcharacteristicsofadvancednonsmallcelllungcancerpatientswithegfrexon20insertions AT kenmasuda clinicalcharacteristicsofadvancednonsmallcelllungcancerpatientswithegfrexon20insertions AT yujimatsumoto clinicalcharacteristicsofadvancednonsmallcelllungcancerpatientswithegfrexon20insertions AT yukishinno clinicalcharacteristicsofadvancednonsmallcelllungcancerpatientswithegfrexon20insertions AT shigehiroyagishita clinicalcharacteristicsofadvancednonsmallcelllungcancerpatientswithegfrexon20insertions AT yusukeokuma clinicalcharacteristicsofadvancednonsmallcelllungcancerpatientswithegfrexon20insertions AT yasushigoto clinicalcharacteristicsofadvancednonsmallcelllungcancerpatientswithegfrexon20insertions AT hidehitohorinouchi clinicalcharacteristicsofadvancednonsmallcelllungcancerpatientswithegfrexon20insertions AT noboruyamamoto clinicalcharacteristicsofadvancednonsmallcelllungcancerpatientswithegfrexon20insertions AT norikomotoi clinicalcharacteristicsofadvancednonsmallcelllungcancerpatientswithegfrexon20insertions AT yasushiyatabe clinicalcharacteristicsofadvancednonsmallcelllungcancerpatientswithegfrexon20insertions AT yuichiroohe clinicalcharacteristicsofadvancednonsmallcelllungcancerpatientswithegfrexon20insertions |
| _version_ |
1718378447562080256 |